J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
OWS Leader Predicts Success
Executive Summary
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
You may also be interested in...
Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.